Fluorodopa (original) (raw)
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Fluorodopa
 |
|
|---|---|
| Clinical data | |
| Trade names | Fluorodopa F18 |
| Other names | 6-fluoro-L-DOPA, FDOPA |
| License data | US DailyMed: Fluorodopa |
| Routes of administration | Intravenous |
| ATC code | V09IX05 (WHO) |
| Legal status | |
| Legal status | US: ℞-only |
| Identifiers | |
| IUPAC name (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid | |
| CAS Number | 92812-82-3 |
| PubChem CID | 56494 |
| DrugBank | DB13848 |
| ChemSpider | 50970 |
| UNII | 2C598205QX |
| KEGG | D04220 |
| ChEBI | CHEBI:49166 |
| ChEMBL | ChEMBL3400972 |
| CompTox Dashboard (EPA) | DTXSID90226257  |
| Chemical and physical data | |
| Formula | C9H10FNO4 |
| Molar mass | 214.18 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N | |
| InChI InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1Key:PAXWQORCRCBOCU-RPDRGXCHSA-N |
Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).[1]
The most common side effects are injection site pain.[2]
Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).[2]
In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).[3][4]
The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS.[3] The trial was conducted at one clinical site in the United States.[3]